Legal Notice
Acceptance of Agreement
Your access to and use of the Onglyza.com Web site (the "Site") is subject to the following terms and conditions and all applicable laws. By accessing and browsing the Site, you accept and agree to, without limitation or qualification, the terms and conditions set forth herein with respect to your access and use of the Site.
Scope of Use
Bristol-Myers Squibb and AstraZeneca maintain the Site for your personal information, education, and communication. Please feel free to browse the Site. You may download material displayed on the Site for noncommercial, personal use only, provided you maintain all copyright and other proprietary notices or disclaimers contained on the materials. You may not, however, distribute, modify, transmit, reuse, repost, or use the content of the Site for public or commercial purposes, including the text and images, without Bristol-Myers Squibb or AstraZeneca's written permission. You understand that Bristol-Myers Squibb and AstraZeneca make no representation that the information in the Site is appropriate or available for use in locations outside of the United States, and access to this Site from territories where the content of the Site may be illegal or inappropriate is unauthorized and at your own risk. Those who choose to access the Site from other locations do so on their own initiative and are responsible for compliance with applicable local laws.
No Medical Advice
The Site does not provide medical advice. With limited exception, Bristol-Myers Squibb and AstraZeneca products are available only by prescription from a licensed health care professional. Bristol-Myers Squibb and AstraZeneca are not engaged in rendering medical or similar professional services or advice, and the information provided on the Site is not intended to replace medical advice offered by a health care provider. If you desire or need such services or advice, you should promptly consult a physician or professional health care provider.
Product Information
The product information provided on the Site is intended only for residents in the United States. The Site and its links may, however, contain information about products that may or may not be available in any particular country, territory, or region of the world (including the United States), may be available under different trademarks in different countries, and, where applicable, may be approved or cleared by a government regulatory body for sale or use with different indications and restrictions in different countries. You should not construe anything on the Site as a promotion or solicitation for any product or service or for the use of any product or service that is not authorized by the laws and regulations of the country where you are located, including the United States. For specific information about particular products, you should refer to the full prescribing information as approved by the relevant governmental authority of the country where you are located. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.
Copyright Protection
You should assume that everything you see or read on the Site is copyrighted, unless otherwise noted, and may not be used except as provided in these terms and conditions or in the text on the Site without the written permission of
Bristol-Myers Squibb and/or AstraZeneca. Bristol-Myers Squibb and/or AstraZeneca neither warrant nor represent that your use of materials displayed on the Site will not infringe rights of third parties not owned by or affiliated with Bristol-Myers Squibb or AstraZeneca.
Trademarks and Other Intellectual Property
The trademarks, trade names, logos, and service marks (collectively the "Trademarks") displayed on the Site are registered and unregistered Trademarks of Bristol-Myers Squibb and/or AstraZeneca and others. This Site may also contain other intellectual property of Bristol-Myers Squibb and/or AstraZeneca. Nothing contained on the Site should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any Trademark or other intellectual property contained on the Site without the written permission of Bristol-Myers Squibb and/or AstraZeneca or such third party that may own the Trademarks or other intellectual property contained on the Site. Your use of the Trademarks displayed on the Site, or any other content on the Site, except as provided in these terms and conditions, is strictly prohibited. You are also advised that Bristol-Myers Squibb and AstraZeneca will aggressively enforce their intellectual property rights to the fullest extent of the law, including the seeking of criminal prosecution.
Exclusion of Warranty
While Bristol-Myers Squibb and AstraZeneca use reasonable efforts to include accurate and up-to-date information in the Site, Bristol-Myers Squibb and AstraZeneca make no warranty or representation as to its accuracy. Bristol-Myers Squibb and AstraZeneca assume no liability or responsibility for any errors or omissions in the content of the Site. Without limiting the foregoing, everything on the Site is provided to you "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. Please note that some jurisdictions may not allow the exclusion of implied warranties, so some of the above exclusions may not apply to you. Check your local laws for any restrictions or limitations regarding the exclusion of implied warranties.
Limitation of Liability
Your use of and browsing in the Site are at your risk. Neither Bristol-Myers Squibb nor AstraZeneca nor any other party involved in creating, producing, or delivering the Site is liable for any direct, incidental, consequential, indirect, or punitive damages arising out of your access to, or use of, the Site. Bristol-Myers Squibb and AstraZeneca assume no responsibility, and shall not be liable for, any damages to, or viruses that may infect, your computer equipment or other property on account of your access to, use of, or browsing in the Site or your downloading of any materials, data, text, or images from the Site.
Prohibited Transmissions
Certain areas of the Site may enable you to access online forums and to submit e-mails or otherwise provide feedback to Bristol-Myers Squibb and AstraZeneca. Bristol-Myers Squibb and AstraZeneca do not endorse, and specifically disclaim, any responsibility or liability for any content in these fora. You may not post or transmit any unlawful, threatening, libelous, defamatory, obscene, indecent, inflammatory, pornographic, or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability, or otherwise violate any law. In addition, you are prohibited from posting or transmitting any information that (a) infringes the rights of others or violates their privacy or publicity rights, (b) is protected by copyright, trademark, or other proprietary right, unless with the express written permission of the owner of such right, (c) contains a virus, bug, or other harmful item, or (d) is used to unlawfully collude against another person in restraint of trade or competition. You shall be solely liable for any damages resulting from any infringement of copyright, trademark, or other proprietary right, or any other harm resulting from your use of the Site.
User Submissions
Any "personally identifiable information" in electronic communications to the Site is governed by the Site's Privacy Statement. Any communication or material you transmit to the Site by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like is, and will be treated as, nonconfidential (except as provided in the Privacy Statement) and nonproprietary. You understand that anything you transmit or post are the property of Bristol-Myers Squibb and AstraZeneca and may be used by Bristol-Myers Squibb and AstraZeneca or their respective affiliates for any purpose, including, but not limited to, reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Bristol-Myers Squibb and AstraZeneca own and are free to use any ideas, concepts, know-how, processes, or techniques contained in any communication you send to the Site for any purpose whatsoever including, but not limited to, developing, manufacturing, marketing, and selling products and service using such ideas, concepts, know-how, processes, or techniques.
Links to Other Sites
Bristol-Myers Squibb and AstraZeneca have not reviewed all of the sites linked to the Site and are not responsible for the content of any off-site pages or any other sites linked to the Site. Your linking to any other off-site pages or other sites is at your own risk. Once you link to another site, please be sure to review the legal notice and privacy statement of the new site. It may be different from those governing this Site.
Governing Law
This Agreement and its performance shall be governed by the laws of the state of New Jersey, United States of America, without regard to its conflict of laws provisions. You consent and submit to the exclusive jurisdiction of the state and federal courts located in the state of New Jersey, United States of America, in all questions and controversies arising out of your use of the Site and this Agreement. To the extent allowed by applicable law, any claim or cause of action arising from or relating to your access or use of the Site must be brought within two (2) years from the date on which such claim or action arose or accrued.
Modification of Agreement
Bristol-Myers Squibb and AstraZeneca may, at any time, revise the terms and conditions of this Agreement governing use of the Site. If any terms and conditions contained in this Legal Notice are changed, the amended notice will be posted on the Site. You are bound by any such revisions and should, therefore, periodically review these terms and conditions.
IMPORTANT INFORMATION ABOUT ONGLYZA™ (saxagliptin)
Indication and Important Limitations of Use
ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
ONGLYZA has not been studied in combination with insulin.
Important Safety Information
  • Use with Medications Known to Cause Hypoglycemia: Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA
  • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug
Most common adverse reactions (regardless of investigator assessment of causality) reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%). When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively.
Drug Interactions: Because ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure, the dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).
Patients with Renal Impairment: The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.
Pregnant and Nursing Women: There are no adequate and well-controlled studies in pregnant women. ONGLYZA, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing woman.
Pediatric Patients: Safety and effectiveness of ONGLYZA in pediatric patients have not been established.